Download
AstraZeneca says vaccine 79% effective, no blood clot risk after U.S. trial
Updated 23:00, 22-Mar-2021
CGTN

Translating...

Content is automatically generated by Microsoft Azure Translator Text API. CGTN is not responsible for any of the translations.

AstraZeneca's COVID-19 vaccine is 79 percent effective in preventing the disease and does not increase the risk of blood clots, the biotech firm said Monday, following its U.S. Phase III efficiency trials. 

The shot was also 80 percent effective for over 65s, it said. Several countries have advised against administering the jab to older people due to a lack of data among elderly participants in previous trials.

Source(s): AFP
TOP NEWS
Boao Forum for Asia Annual Conference 2025 opens in Hainan
{"type":2,"value":"CGTN","commentator":[],"valueShow":true,"commentatorShow":false}

Politics

03:08, 27-Mar-2025

China, France oppose 'decoupling and breaking the chain'
{"type":2,"value":"CGTN","commentator":[],"valueShow":true,"commentatorShow":false}

China

11:02, 27-Mar-2025

Trump's order on imposing 25% tariffs on imported cars sparks fury
{"type":2,"value":"CGTN","commentator":[],"valueShow":true,"commentatorShow":false}

Economy

08:14, 27-Mar-2025

Search Trends